Genetic determinants of Japanese encephalitis virus vaccine strain SA14-14-2 that govern attenuation of virulence in mice

Journal of Virology

Volumn 89, Issue 12, 2015, Pages 6328-6337

  Gromowski, Gregory D ^a   Firestone, Cai Yen ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; REVERSE GENETICS; SURVIVAL RATE; SURVIVAL TIME; TISSUE CULTURE; VERO CELL LINE; VIRUS GENOME; VIRUS REPLICATION; VIRUS VIRULENCE; AEDES; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MUTATION; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRULENCE; VIRUS ENCEPHALITIS; VIRUS GENE;

JAPANESE ENCEPHALITIS VIRUS; MIRIDAE; MUS;

AEDES; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, VIRAL; FEMALE; GENES, VIRAL; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE; MUTATION; VACCINES, ATTENUATED; VIRULENCE;

EID: 84929603368     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00219-15     Document Type: Article

References (39)

1. Rosen L. 1986. The natural history of Japanese encephalitis virus. Annu Rev Microbiol 40:395-414. http://dx.doi.org/10.1146/annurev.mi.40.100186.002143.
2. Buescher EL, Scherer WF. 1959. Ecologic studies of Japanese encephalitis virus in Japan. IX. Epidemiologic correlations and conclusions.AmJ Trop Med Hyg 8:719-722.
3. van den Hurk AF, Ritchie SA, Mackenzie JS. 2009. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 54:17-35. http://dx.doi.org/10.1146/annurev.ento.54.110807.090510.
4. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 89:766-774, 774A-774E. http://dx.doi.org/10.2471/BLT.10.085233.
5. Vaughn DW, Hoke CH, Jr. 1992. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 14:197-221.
6. Villordo SM, Gamarnik AV. 2009. Genome cyclization as strategy for flavivirus RNA replication. Virus Res 139:230-239. http://dx.doi.org/10.1016/j.virusres.2008.07.016.
7. Lindenbach BD, Rice CM. 2003. Molecular biology of flaviviruses. Adv Virus Res 59:23-61. http://dx.doi.org/10.1016/S0065-3527(03)59002-9.
8. Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3:13-22. http://dx.doi.org/10.1038/nrmicro1067.
9. Diamond MS. 2009. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J Interferon Cytokine Res 29:521-530. http://dx.doi.org/10.1089/jir.2009.0069.
10. Ye J, Zhu B, Fu ZF, Chen H, Cao S. 2013. Immune evasion strategies of flaviviruses. Vaccine 31:461-471. http://dx.doi.org/10.1016/j.vaccine.2012.11.015.
11. Beasley DW, Lewthwaite P, Solomon T. 2008. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 8:95-106. http://dx.doi.org/10.1517/14712598.8.1.95.
12. Halstead SB, Thomas SJ. 2011. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 10:355-364. http://dx.doi.org/10.1586/erv.11.7.
13. Appaiahgari MB, Vrati S. 2012. Clinical development of IMOJEV-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Expert Opin Biol Ther 12:1251-1263. http://dx.doi.org/10.1517/14712598.2012.704908.
14. Trent DW, Minor P, Jivapaisarnpong T, Shin J. 2013. WHOworking group on the quality, safety and efficacy of Japanese encephalitis vaccines (live attenuated) for human use, Bangkok, Thailand, 21-23 February 2012. Biologicals 41:450-457. http://dx.doi.org/10.1016/j.biologicals.2013.06.001.
15. Yu Y. 2010. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28:3635-3641. http://dx.doi.org/10.1016/j.vaccine.2010.02.105.
16. Kumar R, Tripathi P, Rizvi A. 2009. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 360:1465-1466. http://dx.doi.org/10.1056/NEJMc0808664.
17. Bista MB, Banerjee MK, Shin SH, Tandan JB, Kim MH, Sohn YM, Ohrr HC, Tang JL, Halstead SB. 2001. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358: 791-795. http://dx.doi.org/10.1016/S0140-6736(01)05967-0.
18. Chotpitayasunondh T, Sohn YM, Yoksan S, Min J, Ohrr H. 2011. Immunizing children aged 9 to 15 months with live attenuated SA14-14-2 Japanese encephalitis vaccine in Thailand. J Med Assoc Thai 94(Suppl 3):S195-S203.
19. Tandan JB, Ohrr H, Sohn YM, Yoksan S, Ji M, Nam CM, Halstead SB. 2007. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25:5041-5045. http://dx.doi.org/10.1016/j.vaccine.2007.04.052.
20. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. 2005. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366:1375-1378. http://dx.doi.org/10.1016/S0140-6736(05)67567-8.
21. WHO. 2014. WHO Expert Committee on Biological Standardization, 63rd report, annex 7, recommendations to assure the quality, safety and efficacy of Japanese encephalitis vaccines (live, attenuated) for human use. WHO Press, Geneva, Switzerland.
22. Aihara S, Rao CM, Yu YX, Lee T, Watanabe K, Komiya T, Sumiyoshi H, Hashimoto H, Nomoto A. 1991. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes 5:95-109. http://dx.doi.org/10.1007/BF00571925.
23. Ni H, Chang GJ, Xie H, Trent DW, Barrett AD. 1995. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol 76(Part 2):409-413.
24. Ni H, Burns NJ, Chang GJ, Zhang MJ, Wills MR, Trent DW, Sanders PG, Barrett AD. 1994. Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J Gen Virol 75(Part 6):1505-1510.
25. Nitayaphan S, Grant JA, Chang GJ, Trent DW. 1990. Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2. Virology 177:541-552.
26. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. 2001. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 75:934-942. http://dx.doi.org/10.1128/JVI.75.2.934-942.2001.
27. Yun SI, Song BH, Kim JK, Yun GN, Lee EY, Li L, Kuhn RJ, Rossmann MG, Morrey JD, Lee YM. 2014. A molecularly cloned, live-attenuated Japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij hairpin of the viral E glycoprotein determines neurovirulence in mice. PLoS Pathog 10:e1004290. http://dx.doi.org/10.1371/journal.ppat.1004290.
28. Yang D, Li XF, Ye Q, Wang HJ, Deng YQ, Zhu SY, Zhang Y, Li SH, Qin CF. 2014. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2. Vaccine 32:2675-2681. http://dx.doi.org/10.1016/j.vaccine.2014.03.074.
29. Chambers TJ, Droll DA, Jiang X, Wold WS, Nickells JA. 2007. JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease. Virology 366:51-61. http://dx.doi.org/10.1016/j.virol.2007.04.016.
30. Ye Q, Li XF, Zhao H, Li SH, Deng YQ, Cao RY, Song KY, Wang HJ, Hua RH, Yu YX, Zhou X, Qin ED, Qin CF. 2012. A single nucleotide mutation in NS2A of Japanese encephalitis-live vaccine virus (SA14-14-2) ablates NS1' formation and contributes to attenuation. J Gen Virol 93: 1959-1964. http://dx.doi.org/10.1099/vir.0.043844-0.
31. Gromowski GD, Firestone CY, Hanson CT, Whitehead SS. 2014. Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine 32:3010-3018. http://dx.doi.org/10.1016/j.vaccine.2014.03.062.
32. Gromowski GD, Firestone CY, Bustos-Arriaga J, Whitehead SS. 2015. Genetic and phenotypic properties of Vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice. Am J Trop Med Hyg 92:98-107. http://dx.doi.org/10.4269/ajtmh.14-0427.
33. Song BH, Yun GN, Kim JK, Yun SI, Lee YM. 2012. Biological and genetic properties of SA(1)(4)-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans. J Microbiol 50:698-706. http://dx.doi.org/10.1007/s12275-012-2336-6.
34. Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. 1988. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6:513-518. http://dx.doi.org/10.1016/0264-410X(88)90103-X.
35. Li XF, Jiang T, Yu XD, Deng YQ, Zhao H, Zhu QY, Qin ED, Qin CF. 2010. RNA elements within the 5' untranslated region of the West Nile virus genome are critical for RNA synthesis and virus replication. J Gen Virol 91:1218-1223. http://dx.doi.org/10.1099/vir.0.013854-0.
36. Li XF, Zhao W, Lin F, Ye Q, Wang HJ, Yang D, Li SH, Zhao H, Xu YP, Ma J, Deng YQ, Zhang Y, Qin ED, Qin CF. 2013. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2. J Gen Virol 94:2700-2709. http://dx.doi.org/10.1099/vir.0.059436-0.
37. Wang HJ, Li XF, Ye Q, Li SH, Deng YQ, Zhao H, Xu YP, Ma J, Qin ED, Qin CF. 2014. Recombinant chimeric Japanese encephalitis virus/tick-borne encephalitis virus is attenuated and protective in mice. Vaccine 32:949-956. http://dx.doi.org/10.1016/j.vaccine.2013.12.050.
38. Li XF, Deng YQ, Yang HQ, Zhao H, Jiang T, Yu XD, Li SH, Ye Q, Zhu SY, Wang HJ, Zhang Y, Ma J, Yu YX, Liu ZY, Li YH, Qin ED, Shi PY, Qin CF. 2013. A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates. J Virol 87:13694-13705. http://dx.doi.org/10.1128/JVI.00931-13.
39. Reed LJ, Muench H. 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27:493-497.